Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 12/20 | 0.43 |
| ▸ | CNR1 | P21554 | 10/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL870642 | 1.00 | NPC1 (0.45) | NPC1RAB9ACNR2CNR1TNKS | |
| SCHEMBL870724 | 0.87 | TNKS (0.49) | NPC1RAB9ACNR2CNR1TNKS | |
| SCHEMBL869972 | 0.87 | TNKS (0.49) | NPC1RAB9ACNR2CNR1TNKS | |
| SCHEMBL4107471 | 0.84 | PDE4B (0.49) | NPC1RAB9ATNKSSMN1; SMN2KDM4E | |
| SCHEMBL4119273 | 0.84 | TNKS (0.46) | NPC1RAB9ACNR2TNKSSMN1; SMN2 | |
| SCHEMBL4119276 | 0.84 | TNKS (0.46) | NPC1RAB9ACNR2TNKSSMN1; SMN2 | |
| SCHEMBL4119280 | 0.84 | TNKS (0.46) | NPC1RAB9ACNR2TNKSSMN1; SMN2 | |
| SCHEMBL4107473 | 0.84 | PDE4B (0.49) | NPC1RAB9ATNKSSMN1; SMN2KDM4E | |
| SCHEMBL4105931 | 0.84 | TNKS (0.46) | NPC1RAB9ACNR2TNKSSMN1; SMN2 | |
| SCHEMBL4105927 | 0.84 | TNKS (0.46) | NPC1RAB9ACNR2TNKSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | NPC1 2462/4885RAB9A 1736/4885CNR2 2229/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | NPC1 2462/4885RAB9A 1736/4885CNR2 2229/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | NPC1 3510/4885RAB9A 1730/4885CNR2 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.